<DOC>
	<DOCNO>NCT02620696</DOCNO>
	<brief_summary>Hypergastrinaemia induce proton pump inhibitor ( PPI ) treatment report cause ECL-cell parietal-cell hyperplasia , rebound hyperacidity dyspepsia PPI withdrawal . The objective study determine dosage regimen netazepide , gastrin/CCK2 receptor antagonist , require inhibit trophic effect PPI-induced hypergastrinaemia . Six group 8 healthy subject participate randomised , double-blind , placebo-controlled exploratory study esomeprazole 40 mg daily 28 day , netazepide 1 , 5 25 mg , placebo daily last 14 day esomeprazole dosing , 14 day esomeprazole withdrawal . Serum gastrin plasma chromogranin A ( CgA ) measure regularly study start least 1 week last dose . Dyspepsia monitor esomeprazole withdrawal .</brief_summary>
	<brief_title>Effect Netazepide Omeprazole-induced Changes Chromogranin A Gastrin</brief_title>
	<detailed_description>Non-clinical study show PPI-induced hypergastrinaemia lead rebound gastric hyperacidity PPI withdrawal . A gastrin/CCK2 receptor antagonist inhibits response . Studies healthy subject patient also suggest PPI withdrawal lead rebound hyperacidity , evidence controversial . However , good evidence study healthy subject PPI withdrawal lead dyspepsia . The principal aim study : assess effect different dose regimen netazepide increase circulate gastrin CgA induce esomeprazole healthy subject ; choose dose regimen future study esomeprazole withdrawal patient . The secondary aim : assess omeprazole withdrawal lead dyspepsia , whether prevented netazepide ; ass likelihood interaction esomeprazole netazepide . Gastrin CgA biomarkers acid suppression increase ECL-cell activity , respectively . This randomised , double-blind , placebo-controlled , parallel-group , pilot study , six group eight healthy subject take esomeprazole 40 mg daily 28 day , netazepide 1 , 5 25 mg , placebo , daily last 14 day esomeprazole dosing , 14 day immediately follow esomeprazole withdrawal ( 25 mg ) . Gastrin CgA measure start dose least one week completion dosing .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>1 . Healthy men , postmenopausal woman premenopausal woman , use one follow method contraception : abstinence ; condom spermicide ; intrauterine device ; hysterectomy tubal ligation 2 . Age 1875 year 3 . A body mass index ( Quetelet index ) range 18.030.9 Body Mass Index = weight ( kg ) /height ( m2 ) 4 . Negative test H. pylori 5 . No history dyspepsia symptoms 6 . No history peptic ulcer oesophagitis 7 . No history treatment histamine H2 antagonist , proton pump inhibitor antacid 8 . Normal serum gastrin ( great 5 % upper limit HMR laboratory reference range gastrin ) 9 . Nonsmokers social smoker ( define 10 few cigarette per week ) 10 . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial 11 . Willingness give write consent participate reading Information Consent Form , opportunity discuss trial investigator delegate . 1 . Women pregnant lactating . 2 . Clinically relevant abnormal history , physical finding , ECG ( &gt; 450 msec ) , laboratory value pretrial screening assessment could interfere objective trial safety subject . 3 . Presence acute chronic illness history chronic illness sufficient invalidate subject 's participation trial make unnecessarily hazardous . 4 . Severe adverse reaction drug 5 . Use , 14 day baseline visit , prescription medicine , especially one inhibits induce CYP3A4/5 , CYP2C8 CYP2C9 , hormone contraceptive hormone replacement therapy . 6 . Use , 14 day baseline visit , herbal product , St John 's wort . 7 . Use overthecounter medicine 7 day baseline visit , exception paracetamol ( 4 g daily ) . 8 . Participation another trial new chemical entity prescription medicine , loss 400 mL blood , within previous 3 month . 9 . Presence history drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>